…
Pangenomic Health Inc. operates as a precision health company in Canada. The company offers Nara App, a telehealth mental health app that provides users with personalized information about non-pharmaceutical alternatives to address mental health concerns; and Mindleap, a telehealth platform, which provides various tools and resources to help individuals understand and improve their inner wellness. It also provides MUJN, a clinical decision support platform that offers health practitioners with access to the consumer's mobile app data and their diagnostic reports. The company was formerly known as Zetta Capital Corp. and changed its name to Pangenomic Health Inc. in December 2021. The company was incorporated in 2015 and is based in Vancouver, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Pangenomic Health Inc. (NARA.CN) are limited, and available materials do not clearly document its core products, services or markets, constraining a reliable assessment of long-term growth drivers. Investors may find the stock of interest if the company provides clearer strategic direction, demonstrable commercial traction or regulatory milestones that could support revenue growth.
The most important investment risk is the paucity of verifiable financial and operational information, which increases execution, financing and liquidity uncertainty and heightens regulatory and market-risk exposure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -3.80M | -2.97M | -11.99M | -2.65M |
| Net income | -3.80M | -2.97M | -11.99M | -2.65M |
| Selling general administrative | 1.12M | 2.46M | 3.03M | 0.72M |
| Reconciled depreciation | 0.01M | 0.01M | 0.01M | 0.00M |
| Operating income | -1.15M | -2.86M | -3.64M | -0.87M |
| Interest expense | 0.07M | 0.04M | 0.00M | 0.00M |
| Interest income | 0.00M | 0.00M | 0.00M | 0.02M |
| Net interest income | -0.07M | -0.04M | 0.00M | 0.01M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.15M | 2.86M | 3.64M | 0.87M |
| Total other income expense net | -2.58M | -0.07M | -8.35M | -1.79M |
| Net income from continuing ops | -3.80M | -2.97M | -11.99M | -2.65M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.04M | 0.07M | 0.50M | 2.58M |
| Intangible assets | - | - | - | 0.85M |
| Total liab | 2.44M | 2.22M | 0.72M | 0.33M |
| Total stockholder equity | -2.41M | -2.14M | -0.22M | 2.24M |
| Capital stock | 14.21M | 12.07M | 11.24M | 5.13M |
| Retained earnings | -21.76M | -17.95M | -14.98M | -2.99M |
| Cash | 0.00M | 0.01M | 0.09M | 1.35M |
| Total current liabilities | 2.44M | 2.22M | 0.72M | 0.33M |
| Net debt | - | 0.95M | 0.01M | - |
| Short long term debt | - | 0.96M | 0.10M | - |
| Total current assets | 0.04M | 0.06M | 0.48M | 1.67M |
| Net receivables | 0.03M | 0.04M | - | - |
| Accounts payable | 1.14M | 0.80M | 0.37M | 0.17M |
| Non current assets total | 0.00M | 0.01M | 0.02M | 0.91M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Net borrowings | 0.05M | 0.96M | 0.14M | 0.02M |
| Total cash from financing activities | 0.05M | 1.50M | 1.57M | 2.97M |
| Net income | -3.80M | -2.97M | -11.99M | -2.65M |
| Change in cash | -0.01M | -0.08M | -1.26M | 1.31M |
| Begin period cash flow | 0.01M | 0.09M | 1.35M | 0.04M |
| End period cash flow | 0.00M | 0.01M | 0.09M | 1.35M |
| Total cash from operating activities | -0.06M | -1.57M | -2.78M | -1.06M |
| Issuance of capital stock | 0.00M | 0.20M | 1.29M | 2.95M |
| Depreciation | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.01M | 0.01M |
| Change in working capital | 1.24M | 1.14M | 0.23M | -0.26M |
| Stock based compensation | -0.14M | 0.17M | 0.62M | 0.05M |
| Other non cash items | 0.07M | 0.04M | 0.03M | 0.00M |
| Free cash flow | -0.06M | -1.57M | -2.79M | -1.07M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NARA Pangenomic Health Inc. |
- -% |
0.30 | - | - | - | 5.38 | -0.11 |
| AIDR Rocket Doctor AI Inc |
-0.01 1.06% |
0.47 | - | - | 1671.77 | 6.46 | -0.39 |
| DMED Diagnamed Holdings Corp. |
-0.01 14.29% |
0.03 | - | - | - | 10.74 | -1.43 |
| AIML AI/ML Innovations Inc |
- -% |
0.04 | - | - | 70.85 | 35.17 | -3.59 |
| UDOC UniDoc Health Corp. |
0.01 11.11% |
0.05 | - | - | 10.64 | 668.99 | -9.56 |
Pangenomic Health Inc. operates as a precision health company in Canada. The company offers Nara App, a telehealth mental health app that provides users with personalized information about non-pharmaceutical alternatives to address mental health concerns; and Mindleap, a telehealth platform, which provides various tools and resources to help individuals understand and improve their inner wellness. It also provides MUJN, a clinical decision support platform that offers health practitioners with access to the consumer's mobile app data and their diagnostic reports. The company was formerly known as Zetta Capital Corp. and changed its name to Pangenomic Health Inc. in December 2021. The company was incorporated in 2015 and is based in Vancouver, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert Carl Nygren | Co-Founder & Executive Chairman | 1963 |
| Ms. Maryam Marissen | CEO, President & Director | NA |
| Mr. Vincent L. Lum | Co-Founder | 1961 |
| Ms. Tammy Gillis C.M.A., CPA | Treasurer & Secretary | 1974 |
| Mr. Derek Ho | Director of Operations | NA |
| Mr. Kaidong Zhang | Chief Scientific Officer | 1978 |
| Mr. Colin Quon | Chief Technology Officer of MUJN Diagnostics | 1968 |
| Mr. Robert Carl Nygren | Co-Founder & Executive Chairman | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.